MultiplexDX
About the investment opportunity
MultiplexDX, a leading biotechnology company, is developing Multiplex8+, a unique and innovative diagnostic that combines unique RNA biomarker sequencing and visualization methods for more effective treatment of breast cancer.
MultiplexDX has completed an extensive retrospective clinical validation of the Multiplex8+ diagnostic test for breast cancer patients, making breast cancer diagnosis even more accurate and precise. This is extremely important for developing effective, life-saving treatment. MultiplexDX has completed a large European EIC Accelerator grant, becoming the first Slovak company to win such a grant when it was awarded one in 2020 out of 2,000 applicants from across Europe. The award of the grant was preceded by a rigorous evaluation of excellence by a panel of international independent experts. Today, the company is sending the first diagnostic results to the first patient to help fight this insidious disease.
This opens a new chapter not only for MutiplexDX itself, a company dedicated to the diagnosis and treatment of cancer, but also for investors attracted to the biotech sector.
Multiplex8+ diagnostic test
To view this section, please register
To view this section, please register
MultiplexDX at a glance
To view this section, please register
Company and its goals
To view this section, please register
The product
To view this section, please register
Tým
To view this section, please register
Market and competition
To view this section, please register
Risks
To view this section, please register
Intent of investment
To view this section, please register
Media
Innovative Slovakia: MultiplexDX zaradený medzi TOP slovenské startupy